Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Reinstatement to Quotation

Tuesday, June 25, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has been reinstated to quotation following positive developments in its clinical programs. The company has received IND approval from the US FDA to initiate a Phase I therapeutic study targeting B7H3 with its product BetaBart (RV-01). Additionally, the company has successfully dosed its first patient in a Phase 1/2a clinical study.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is initiating a Phase I therapeutic clinical study.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• Price Sensitive
• June 25, 2024
Loading Viewer…

More Announcements & Updates

• Analyst Reports
• November 3, 2025
• Announcements
• April 27, 2023
• Announcements
• November 16, 2023
• Announcements
• December 30, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent approval did Radiopharm receive?

Radiopharm Theranostics received IND approval from the US FDA.

What is the focus of the Phase I study?

The Phase I study targets B7H3 with the product BetaBart (RV-01).

Has Radiopharm started patient dosing?

Yes, Radiopharm has dosed its first patient in a Phase 1/2a clinical study.

What updates has Radiopharm provided?

Radiopharm has provided positive clinical updates across four programs.

Tags: RADX Viatris Investor Conferences Healthcare FDA approval Phase I study BetaBart clinical updates
Last updated: Jun 25, 2024